These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31244689)

  • 21. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.
    Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E
    Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: a prospective follow-up study.
    Li X; Yan D; Liao M; Zhang L; Li Z; Liu B; Chen Y; Zhang Y; Liu J; Li L
    Front Psychiatry; 2023; 14():1163754. PubMed ID: 37304432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leveraging Machine Learning Approaches for Predicting Antidepressant Treatment Response Using Electroencephalography (EEG) and Clinical Data.
    Jaworska N; de la Salle S; Ibrahim MH; Blier P; Knott V
    Front Psychiatry; 2018; 9():768. PubMed ID: 30692945
    [No Abstract]   [Full Text] [Related]  

  • 25. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
    J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features and drug induced side effects in early versus late antidepressant responders.
    Fabbri C; Marsano A; Balestri M; De Ronchi D; Serretti A
    J Psychiatr Res; 2013 Oct; 47(10):1309-18. PubMed ID: 23800418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression.
    Schmidt FM; Schröder T; Kirkby KC; Sander C; Suslow T; Holdt LM; Teupser D; Hegerl U; Himmerich H
    Psychiatry Res; 2016 May; 239():85-91. PubMed ID: 27137966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs.
    Yoshimura R; Kishi T; Hori H; Katsuki A; Sugita-Ikenouchi A; Umene-Nakano W; Atake K; Iwata N; Nakamura J
    Psychiatry Investig; 2014 Jan; 11(1):84-8. PubMed ID: 24605128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy.
    Grosse L; Carvalho LA; Birkenhager TK; Hoogendijk WJ; Kushner SA; Drexhage HA; Bergink V
    Psychopharmacology (Berl); 2016 May; 233(9):1679-88. PubMed ID: 25953327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine plasma level and antidepressant response.
    De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Shan XX; Qiu Y; Xie WW; Wu RR; Yu Y; Wu HS; Li LH
    Front Pharmacol; 2019; 10():761. PubMed ID: 31333472
    [No Abstract]   [Full Text] [Related]  

  • 32. Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study.
    Kim K; Jang EH; Kim AY; Fava M; Mischoulon D; Papakostas GI; Kim H; Na EJ; Yu HY; Jeon HJ
    Compr Psychiatry; 2019 Nov; 95():152140. PubMed ID: 31669792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hippocampal volume predicts antidepressant efficacy in depressed patients without incomplete hippocampal inversion.
    Colle R; Cury C; Chupin M; Deflesselle E; Hardy P; Nasser G; Falissard B; Ducreux D; Colliot O; Corruble E
    Neuroimage Clin; 2016; 12():949-955. PubMed ID: 27995060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.
    Alcocer-Gómez E; Casas-Barquero N; Williams MR; Romero-Guillena SL; Cañadas-Lozano D; Bullón P; Sánchez-Alcazar JA; Navarro-Pando JM; Cordero MD
    Pharmacol Res; 2017 Jul; 121():114-121. PubMed ID: 28465217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium.
    Arteaga-Henríquez G; Simon MS; Burger B; Weidinger E; Wijkhuijs A; Arolt V; Birkenhager TK; Musil R; Müller N; Drexhage HA
    Front Psychiatry; 2019; 10():458. PubMed ID: 31354538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Necrosis Factor-α Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment.
    Yao L; Pan L; Qian M; Sun W; Gu C; Chen L; Tang X; Hu Y; Xu L; Wei Y; Hui L; Liu X; Wang J; Zhang T
    Front Psychiatry; 2020; 11():518837. PubMed ID: 33364982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder.
    Kim JW; Kim YK; Hwang JA; Yoon HK; Ko YH; Han C; Lee HJ; Ham BJ; Lee HS
    Psychiatry Investig; 2013 Sep; 10(3):294-9. PubMed ID: 24302954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.
    Chen CY; Yeh YW; Kuo SC; Liang CS; Ho PS; Huang CC; Yen CH; Shyu JF; Lu RB; Huang SY
    Psychoneuroendocrinology; 2018 Jan; 87():108-118. PubMed ID: 29055264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.
    Caudill MM; Hunter AM; Cook IA; Leuchter AF
    Clin EEG Neurosci; 2015 Oct; 46(4):277-84. PubMed ID: 25258429
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.